Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb;261(2):555-560.
doi: 10.1007/s00417-022-05798-0. Epub 2022 Aug 8.

New onset of acute uveitis following COVID-19 vaccination

Ha Eun Sim  1 , Je Hyung Hwang  2
Affiliations

New onset of acute uveitis following COVID-19 vaccination

Ha Eun Sim et al. Graefes Arch Clin Exp Ophthalmol. 2023 Feb.

Abstract

Purpose: This study reported 11 cases of new-onset acute uveitis following coronavirus disease 2019 (COVID-19) vaccination.

Methods: This retrospective observational case study included 11 eyes of 11 patients with acute uveitis after the COVID-19 vaccination. We only included patients with new-onset uveitis. The medical records of the patients from January 2021 to January 2022 were reviewed.

Results: The mean age of the participants was 51.81 years, and all patients demonstrated anterior chamber reaction with keratic precipitates in the affected eye. The mean duration between vaccination and uveitis was 8.27 days. Seven patients developed uveitis after receiving the second dose of vaccination, and four developed uveitis after receiving the third dose of vaccination. Five patients showed posterior synechiae, and three patients showed hypopyon. After treatment with topical 1% prednisolone acetate eye drops and systemic prednisolone, inflammation was adequately controlled and quickly resolved.

Conclusions: COVID-19 vaccination with messenger RNA and viral vector vaccines may cause acute anterior uveitis. Although initially severe, uveitis responded well to steroid therapy with no visual impairment.

Keywords: COVID-19; Uveitis; Vaccination.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Clinical presentation of acute uveitis at the initial visit: slit-lamp photography of patients 1–5, 7–9, and 11. All patients showing anterior chamber cells
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Hodgson SH, Mansatta K, Mallett G, Harris V, Emary KRW, Pollard AJ. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Lancet Infect Dis. 2021;21:e26–e35. doi: 10.1016/S1473-3099(20)30773-8. - DOI - PMC - PubMed
    1. Aslam S, Goldstein DR, Vos R, Gelman AE, Kittleson MM, Wolfe C, Danziger-Isakov L. COVID-19 vaccination in our transplant recipients: the time is now. J Heart Lung Transplant. 2021;40:169–171. doi: 10.1016/j.healun.2020.12.009. - DOI - PMC - PubMed
    1. Calina DAO, Docea D, Petrakis D, Egorov AM, Ishmukhametov AA, GabibovShtilmanKostoffCarvalhoVincetiSpandidosTsatsakis AGMIRFMDAA. Towards effective COVID19 vaccines: updates, perspectives and challenges (review) Int J Mol Med. 2020;46:3–16. doi: 10.3892/ijmm.2020.4596. - DOI - PMC - PubMed
    1. Ramasamy MN, Minassian AM, Ewer KJ, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021;396:1979–1993. doi: 10.1016/S0140-6736(20)32466-1. - DOI - PMC - PubMed
    1. Voysey M, Costa Clemens SA, Madhi SA, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021;397:881–891. doi: 10.1016/S0140-6736(21)00432-3. - DOI - PMC - PubMed

Substances